STATEMENT _ O
FROM _ O
THE _ O
EXECUTIVE _ O
CHAIRMAN _ O
Prudence _ O
in _ O
Every _ O
Decision _ O
. _ O

Consistency _ O
in _ O
Every _ O
Action _ O
. _ O

Dear _ O
Stakeholders _ O
, _ O
I _ O
write _ O
to _ O
you _ O
at _ O
a _ O
time _ O
when _ O
our _ O
external _ O
environment _ O
is _ O
recovering _ O
from _ O
a _ O
once-in-a-century _ O
event _ O
in _ O
the _ O
form _ O
of _ O
COVID _ O
- _ O
19 _ O
. _ O

Even _ O
as _ O
uncertainty _ O
persists _ O
in _ O
the _ O
wake _ O
of _ O
a _ O
second _ O
wave _ O
, _ O
we _ O
can _ O
say _ O
with _ O
reasonable _ O
confidence _ O
that _ O
as _ O
a _ O
nation _ O
, _ O
we _ O
are _ O
better _ O
prepared _ O
. _ O

Constant _ O
change _ O
has _ O
been _ O
accepted _ O
as _ O
the _ O
new _ O
normal _ O
, _ O
with _ O
businesses _ O
, _ O
governments _ O
and _ O
societies _ O
shifting _ O
gears _ O
to _ O
quickly _ O
adapt _ O
. _ O

The _ O
concept _ O
of _ O
value _ O
is _ O
also _ O
changing _ O
, _ O
with _ O
Environmental _ O
, _ O
Social _ O
and _ O
Governance _ O
( _ O
ESG _ O
) _ O
parameters _ O
emerging _ O
as _ O
tenets _ O
of _ O
business _ O
viability _ O
. _ O

In _ O
this _ O
backdrop _ O
, _ O
I _ O
would _ O
like _ O
to _ O
introduce _ O
you _ O
to _ O
Torrent _ O
Pharma _ O
’ _ O
s _ O
first-ever _ O
Integrated _ O
Annual _ O
Report _ O
that _ O
articulates _ O
how _ O
we _ O
perceive _ O
and _ O
aim _ O
to _ O
create _ O
value _ O
. _ O

This _ O
Report _ O
reflects _ O
how _ O
we _ O
have _ O
approached _ O
stakeholder _ O
value _ O
creation _ O
over _ O
the _ O
years _ O
, _ O
and _ O
includes _ O
a _ O
detailed _ O
review _ O
of _ O
our _ O
financial _ O
and _ O
non-financial _ O
performance _ O
, _ O
together _ O
with _ O
the _ O
strategic _ O
way _ O
forward _ O
. _ O

Economic _ O
context _ O
Globally _ O
, _ O
economic _ O
revival _ O
is _ O
taking _ O
place _ O
in _ O
two _ O
tangents _ O
– _ O
the _ O
developed _ O
countries _ O
bouncing _ O
back _ O
faster _ O
and _ O
the _ O
developing _ O
economies _ O
continuing _ O
to _ O
battle _ O
ground _ O
realities _ O
. _ O

In _ O
India _ O
, _ O
a _ O
multitude _ O
of _ O
measures _ O
from _ O
the _ O
government _ O
helped _ O
balance _ O
lives _ O
and _ O
livelihoods _ O
, _ O
and _ O
the _ O
vaccination _ O
roll-out _ O
serves _ O
as _ O
a _ O
ray _ O
of _ O
hope _ O
. _ O

The _ O
projections _ O
by _ O
global _ O
agencies _ O
, _ O
such _ O
as _ O
the _ O
IMF _ O
and _ O
the _ O
national _ O
estimates _ O
indicate _ O
high _ O
single-digit _ O
to _ O
double-digit _ O
growth _ O
for _ O
India _ O
in _ O
2021 _ O
- _ O
22 _ O
, _ O
after _ O
the _ O
shocks _ O
of _ O
2020 _ O
- _ O
21 _ O
. _ O

In _ O
a _ O
context _ O
mired _ O
with _ O
the _ O
pandemic _ O
, _ O
the _ O
role _ O
of _ O
healthcare _ B-key
and _ O
pharmaceuticals _ B-key
have _ O
become _ O
even _ O
more _ O
pronounced _ O
. _ O

The _ O
social _ O
value _ O
these _ O
sectors _ O
bring _ O
has _ O
been _ O
validated _ O
like _ O
never _ O
before _ O
, _ O
and _ O
the _ O
strengthening _ O
of _ O
the _ O
healthcare _ O
ecosystem _ O
has _ O
become _ O
a _ O
core _ O
priority _ O
, _ O
even _ O
reflecting _ O
in _ O
national _ O
budget _ O
allocations _ O
. _ O

A _ O
model _ O
of _ O
growth _ O
and _ O
resilience _ O
Starting _ O
in _ O
the _ O
domestic _ O
Indian _ O
market _ O
in _ O
the _ O
early _ O
1970s _ O
and _ O
foraying _ O
into _ O
exports _ O
in _ O
1980s _ O
, _ O
Torrent _ O
Pharma _ O
has _ O
come _ O
a _ O
long _ O
way _ O
today _ O
, _ O
with _ O
presence _ O
in _ O
more _ O
than _ O
40 _ O
countries _ O
and _ O
emerging _ O
as _ O
one _ O
of _ O
India _ O
’ _ O
s _ O
pharma _ O
majors _ O
. _ O

Our _ O
business _ O
spans _ O
Branded _ O
Generic _ O
( _ O
BGx _ O
) _ O
and _ O
Generic _ O
( _ O
Gx _ O
) _ O
markets _ O
, _ O
with _ O
the _ O
former _ O
having _ O
predominant _ O
presence _ O
. _ O

Strong _ O
chronic _ O
and _ O
sub-chronic _ O
portfolio _ O
and _ O
specialty _ O
driven _ O
approach _ O
in _ O
BGx _ O
markets _ O
, _ O
along _ O
with _ O
a _ O
robust _ O
and _ O
diversified _ O
portfolio _ O
as _ O
well _ O
as _ O
moving _ O
towards _ O
complex _ O
product _ O
pipelines _ O
in _ O
Gx _ O
markets _ O
serve _ O
as _ O
the _ O
bedrock _ O
of _ O
our _ O
business _ O
competitiveness _ O
and _ O
sustainability _ O
. _ O

Our _ O
approach _ O
of _ O
‘ _ O
Not _ O
Just _ O
Healthcare _ O
. _ O
. _ O
. _ O

Lifecare _ O
’ _ O
, _ O
is _ O
underpinned _ O
by _ O
the _ O
highest _ O
levels _ O
of _ O
product _ O
and _ O
research _ O
excellence _ O
, _ O
and _ O
is _ O
guided _ O
by _ O
the _ O
motto _ O
of _ O
' _ O
one _ O
product _ O
, _ O
one _ O
globe _ O
, _ O
one _ O
quality _ O
' _ O
. _ O

Our _ O
resilience _ O
is _ O
underlined _ O
by _ O
our _ O
ability _ O
to _ O
adapt _ O
, _ O
evolve _ O
and _ O
mitigate _ O
risks _ O
, _ O
with _ O
patient _ O
centricity _ O
at _ O
the _ O
core _ O
. _ O

These _ O
aspects _ O
combine _ O
with _ O
our _ O
focused _ O
stakeholder _ O
relationships _ O
, _ O
and _ O
holds _ O
us _ O
in _ O
good _ O
stead _ O
. _ O

To _ O
maintain _ O
our _ O
connect _ O
with _ O
the _ O
medical _ O
community _ O
, _ O
we _ O
engage _ O
our _ O
specialised _ O
field _ O
force _ O
, _ O
thus _ O
setting _ O
in _ O
motion _ O
a _ O
virtuous _ O
cycle _ O
and _ O
creating _ O
strong _ O
moat _ O
. _ O

From _ O
a _ O
strategic _ O
point _ O
of _ O
view _ O
, _ O
we _ O
continue _ O
to _ O
focus _ O
on _ O
our _ O
stronghold _ O
markets _ O
with _ O
a _ O
BGx _ O
concentration _ O
. _ O

Market _ O
share _ O
gains _ O
by _ O
aiming _ O
to _ O
grow _ O
faster _ O
than _ O
the _ O
market _ O
, _ O
therapy _ O
consolidation _ O
, _ O
therapy _ O
expansion _ O
and _ O
sustained _ O
investment _ B-key
in _ O
new _ O
products _ O
continue _ O
to _ O
be _ O
our _ O
measures _ O
of _ O
progress _ O
in _ O
these _ O
markets _ O
. _ O

Our _ O
market _ O
expansion _ O
strategy _ O
seeks _ O
to _ O
extend _ O
our _ O
presence _ O
in _ O
geographies _ O
contiguous _ O
with _ O
our _ O
existing _ O
markets _ O
and _ O
with _ O
a _ O
similar _ O
policy _ O
environment _ O
. _ O

Although _ O
organic _ O
growth _ O
is _ O
inherent _ O
to _ O
our _ O
nature _ O
of _ O
doing _ O
business _ O
, _ O
we _ O
believe _ O
inorganic _ B-key
growth _ O
will _ O
continue _ O
to _ O
be _ O
an _ O
integral _ O
part _ O
of _ O
our _ O
overall _ O
growth _ O
story _ O
. _ O

Complementing _ O
our _ O
growth _ O
plans _ O
, _ O
our _ O
people _ O
approach _ O
, _ O
deployment _ O
of _ O
contemporary _ O
technology _ O
and _ O
operational _ O
excellence _ O
act _ O
as _ O
strategic _ O
priorities _ O
that _ O
propel _ O
us _ O
forward _ O
. _ O

Performing _ O
across _ O
key _ O
financial _ O
indicators _ O
While _ O
pandemic-induced _ O
uncertainties _ O
and _ O
related _ O
economic _ O
slowdown _ O
impacted _ O
the _ O
growth _ O
of _ O
global _ O
pharmaceutical _ O
markets _ O
during _ O
the _ O
year _ O
, _ O
I _ O
’ _ O
m _ O
pleased _ O
to _ O
report _ O
that _ O
we _ O
continued _ O
to _ O
perform _ O
with _ O
resilience _ O
, _ O
anchored _ O
on _ O
our _ O
chronic-based _ O
business _ O
model _ O
, _ O
patient _ O
centricity _ O
and _ O
business _ O
continuity _ O
processes _ O
. _ O

The _ O
underlying _ O
growth _ O
in _ O
our _ O
core _ O
markets _ O
of _ O
India _ O
, _ O
Brazil _ O
and _ O
Germany _ O
has _ O
been _ O
strong _ O
and _ O
continue _ O
to _ O
outperform _ O
12 _ O
Integrated _ O
Annual _ O
Report _ O
2020 _ O
- _ O
21 _ O
the _ O
market _ O
. _ O

The _ O
growth _ O
in _ O
the _ O
US _ O
was _ O
impacted _ O
due _ O
to _ O
lack _ O
of _ O
new _ O
approvals _ O
, _ O
pending _ O
re-inspection _ O
of _ O
facilities _ O
by _ O
USFDA _ O
. _ O

Overall _ O
, _ O
we _ O
achieved _ O
a _ O
revenue _ B-key
of _ O
` _ O
8,005 _ O
crores _ O
in _ O
2020 _ O
- _ O
21 _ O
, _ O
while _ O
witnessing _ O
significant _ O
improvement _ O
across _ O
operating _ O
and _ O
net _ O
earnings _ O
( _ O
11% _ O
and _ O
22% _ O
Y-o-Y _ O
respectively _ O
) _ O
. _ O

Earnings _ O
growth _ O
was _ O
complemented _ O
by _ O
pandemic-led _ O
cost _ O
savings _ O
, _ O
productivity _ O
improvements _ O
and _ O
operating _ O
leverage _ O
. _ O

The _ O
year _ O
gone _ O
by _ O
has _ O
also _ O
made _ O
us _ O
explore _ O
means _ O
to _ O
create _ O
more _ O
efficient _ O
ways _ O
of _ O
working _ O
that _ O
could _ O
potentially _ O
lead _ O
to _ O
longer _ O
term _ O
cost _ O
savings _ O
. _ O

We _ O
continue _ O
to _ O
allocate _ O
incremental _ O
cash _ O
flows _ O
to _ O
de-leverage _ O
our _ O
balance _ O
sheet _ O
, _ O
with _ O
a _ O
net _ O
debt _ O
to _ O
EBITDA _ O
of _ O
1.6x _ O
by _ O
the _ O
end _ O
of _ O
2020 _ O
- _ O
21 _ O
versus _ O
2.2x _ O
in _ O
the _ O
previous _ O
year _ O
. _ O

We _ O
also _ O
continued _ O
to _ O
enhance _ O
our _ O
shareholder _ O
value _ O
during _ O
the _ O
year _ O
. _ O

For _ O
2020 _ O
- _ O
21 _ O
, _ O
the _ O
Board _ O
has _ O
recommended _ O
a _ O
total _ O
dividend _ O
of _ O
` _ O
35 _ O
per _ O
equity _ O
share _ O
for _ O
shareholders _ O
’ _ O
approval _ O
. _ O

With _ O
India _ O
to _ O
battle _ O
the _ O
pandemic _ O
As _ O
a _ O
responsible _ O
corporate _ O
citizen _ O
, _ O
we _ O
are _ O
standing _ O
with _ O
the _ O
nation _ O
in _ O
its _ O
fight _ O
against _ O
COVID _ O
- _ O
19 _ O
, _ O
through _ O
specific _ O
interventions _ O
. _ O

Torrent _ O
committed _ O
` _ O
100 _ O
crores _ O
to _ O
fight _ O
the _ O
pandemic _ O
, _ O
at _ O
a _ O
Group _ O
level _ O
. _ O

This _ O
contribution _ O
was _ O
made _ O
to _ O
the _ O
PM-CARES _ O
Fund _ O
and _ O
for _ O
various _ O
initiatives _ O
, _ O
such _ O
as _ O
providing _ O
essential _ O
medicines _ O
to _ O
various _ O
government _ O
hospitals _ O
, _ O
contributions _ O
to _ O
state _ O
relief _ O
funds _ O
and _ O
NGOs _ O
, _ O
provision _ O
of _ O
PPEs _ O
to _ O
healthcare _ O
workers _ O
, _ O
apart _ O
from _ O
the _ O
Group _ O
’ _ O
s _ O
ground-level _ O
initiatives _ O
. _ O

As _ O
India _ O
faced _ O
a _ O
dearth _ O
of _ O
medical-grade _ O
oxygen _ O
, _ O
Torrent _ O
Group _ O
stepped _ O
up _ O
and _ O
augmented _ O
its _ O
oxygen _ O
production _ O
and _ O
supply _ O
capacity _ O
to _ O
meet _ O
the _ O
daily _ O
oxygen _ O
requirements _ O
of _ O
10,000 _ O
patients _ O
. _ O

It _ O
is _ O
setting _ O
up _ O
50 _ O
medical _ O
oxygen _ O
production _ O
plants _ O
for _ O
50 _ O
government _ O
hospitals _ O
, _ O
spanning _ O
seven _ O
states _ O
and _ O
have _ O
deployed _ O
two _ O
cryogenic _ O
tankers _ O
of _ O
18 _ O
metric _ O
tonnes _ O
each _ O
for _ O
transportation _ O
of _ O
liquid _ O
medical _ O
oxygen _ O
. _ O

We _ O
are _ O
also _ O
providing _ O
free _ O
oxygen _ O
using _ O
an _ O
oxygen _ O
generation _ O
plant _ O
and _ O
bottling _ O
facility _ O
in _ O
Ahmedabad _ O
. _ O

We _ O
have _ O
partnered _ O
with _ O
Eli _ O
Lilly _ O
and _ O
Company _ O
to _ O
manufacture _ O
and _ O
commercialise _ O
‘ _ O
Baricitinib _ O
’ _ O
( _ O
an _ O
emergency _ O
use _ O
approved _ O
drug _ O
given _ O
in _ O
combination _ O
with _ O
Remdesivir _ O
for _ O
COVID _ O
- _ O
19 _ O
) _ O
in _ O
India _ O
, _ O
under _ O
a _ O
royalty-free _ O
, _ O
non-exclusive _ O
voluntary _ O
licensing _ O
agreement _ O
. _ O

This _ O
, _ O
along _ O
with _ O
other _ O
such _ O
partnerships _ O
planned _ O
through _ O
the _ O
year _ O
, _ O
further _ O
strengthens _ O
our _ O
commitment _ O
and _ O
effort _ O
to _ O
help _ O
the _ O
nation _ O
fight _ O
the _ O
pandemic _ O
. _ O

Sustainability _ O
with _ O
a _ O
core _ O
focus _ O
on _ O
ESG _ O
At _ O
Torrent _ O
Pharma _ O
, _ O
business _ O
responsibility _ O
is _ O
not _ O
a _ O
new _ O
concept _ O
. _ O

Changing _ O
nomenclatures _ O
notwithstanding _ O
, _ O
we _ O
have _ O
always _ O
focused _ O
on _ O
building _ O
the _ O
nation _ O
, _ O
protecting _ O
the _ O
environment _ O
, _ O
contributing _ O
to _ O
society _ O
and _ O
conducting _ O
business _ O
with _ O
integrity _ O
. _ O

We _ O
firmly _ O
believe _ O
in _ O
achieving _ O
long-term _ O
business _ O
success _ O
together _ O
with _ O
everyone _ O
. _ O

As _ O
a _ O
manufacturing _ O
entity _ O
, _ O
we _ O
have _ O
a _ O
sizeable _ O
environmental _ O
footprint _ O
, _ O
which _ O
we _ O
manage _ O
scientifically _ O
. _ O

Our _ O
core _ O
environmental _ O
focus _ O
areas _ O
include _ O
climate _ O
change _ O
and _ O
energy _ O
management _ O
, _ O
emissions _ O
, _ O
waste _ O
and _ O
water _ O
management _ O
. _ O

Through _ O
dedicated _ O
interventions _ O
, _ O
we _ O
have _ O
been _ O
able _ O
to _ O
achieve _ O
significant _ O
savings _ O
in _ O
our _ O
carbon _ O
footprint _ O
. _ O

With _ O
state-of-the-art _ O
systems _ O
, _ O
we _ O
also _ O
managed _ O
our _ O
waste _ O
effectively _ O
, _ O
with _ O
over _ O
55% _ O
of _ O
the _ O
waste _ O
produced _ O
being _ O
recycled _ O
. _ O

We _ O
recycle _ O
~ _ O
87% _ O
of _ O
water _ O
consumed _ O
and _ O
have _ O
erected _ O
rainwater _ O
harvesting _ O
structures _ O
, _ O
to _ O
de-stress _ O
the _ O
water _ O
table _ O
in _ O
our _ O
areas _ O
of _ O
operations _ O
. _ O

On _ O
the _ O
social _ O
front _ O
, _ O
we _ O
have _ O
been _ O
dedicated _ O
to _ O
creating _ O
lasting _ O
value _ O
since _ O
inception _ O
, _ O
and _ O
social _ O
well-being _ O
continues _ O
to _ O
be _ O
a _ O
top _ O
priority _ O
on _ O
our _ O
radar _ O
. _ O

We _ O
impacted _ O
71,000 _ O
lives _ O
through _ O
our _ O
CSR _ O
programmes _ O
, _ O
with _ O
our _ O
flagship _ O
REACH _ O
initiative _ O
benefiting _ O
several _ O
villages _ O
. _ O

Focused _ O
on _ O
child _ B-key
healthcare _ I-key
, _ O
the _ O
REACH _ O
initiative _ O
continues _ O
to _ O
positively _ O
impact _ O
people's _ O
lives _ O
across _ O
our _ O
intervention _ O
areas _ O
, _ O
actively _ O
fighting _ O
malnutrition _ O
and _ O
pediatric _ O
illnesses _ O
. _ O

We _ O
also _ O
extend _ O
our _ O
CSR _ O
programmes _ O
to _ O
infrastructure _ B-key
and _ O
public _ B-key
space _ I-key
development _ I-key
, _ O
and _ O
through _ O
contributions _ O
to _ O
hospitals _ B-key
and _ O
institutions _ O
. _ O

From _ O
a _ O
people _ O
stand _ O
point _ O
, _ O
we _ O
assert _ O
that _ O
the _ O
well-being _ O
of _ O
our _ O
employees _ O
takes _ O
maximum _ O
priority _ O
. _ O

We _ O
organise _ O
regular _ O
safety _ O
trainings _ O
and _ O
conduct _ O
audits _ O
to _ O
ensure _ O
a _ O
safe _ O
workplace _ O
for _ O
all _ O
. _ O

From _ O
an _ O
inclusion _ O
lens _ O
, _ O
we _ O
view _ O
diversity _ O
as _ O
an _ O
enabler _ O
of _ O
growth _ O
, _ O
and _ O
foster _ O
a _ O
zero _ O
discrimination _ O
policy _ O
. _ O

We _ O
are _ O
powered _ O
by _ O
the _ O
spirit _ O
of _ O
a _ O
13,500 _ O
+ _ O
workforce _ O
, _ O
of _ O
whom _ O
~ _ O
21% _ O
is _ O
below _ O
30 _ O
years _ O
of _ O
age _ O
. _ O

We _ O
also _ O
inculcate _ O
a _ O
meritocratic _ O
culture _ O
, _ O
and _ O
constantly _ O
reward _ O
and _ O
recognise _ O
our _ O
people _ O
for _ O
their _ O
contributions _ O
. _ O

Our _ O
business _ O
conduct _ O
and _ O
corporate _ O
behaviour _ O
continue _ O
to _ O
garner _ O
trust _ O
of _ O
the _ O
stakeholders _ O
and _ O
is _ O
led _ O
by _ O
a _ O
strong _ O
Board _ O
. _ O

Looking _ O
forward _ O
We _ O
look _ O
at _ O
the _ O
future _ O
with _ O
a _ O
very _ O
optimistic _ O
stance _ O
, _ O
recognising _ O
healthcare _ O
as _ O
a _ O
universal _ O
human _ O
need _ O
and _ O
as _ O
a _ O
space _ O
where _ O
we _ O
can _ O
serve _ O
our _ O
purpose _ O
. _ O

As _ O
we _ O
grow _ O
and _ O
expand _ O
, _ O
our _ O
singular _ O
focus _ O
will _ O
be _ O
on _ O
bettering _ O
patient _ O
lives _ O
through _ O
strong _ O
R _ O
& _ O
D _ O
and _ O
highest _ O
product _ O
quality _ O
. _ O

We _ O
will _ O
further _ O
strengthen _ O
our _ O
stakeholder _ O
relationships _ O
and _ O
continuously _ O
create _ O
win-win _ O
propositions _ O
for _ O
the _ O
benefit _ O
of _ O
all _ O
. _ O

Our _ O
values _ O
, _ O
legacy _ O
and _ O
responsibility _ O
will _ O
continue _ O
to _ O
guide _ O
us _ O
and _ O
together _ O
, _ O
we _ O
will _ O
strive _ O
to _ O
enable _ O
life _ O
care _ O
for _ O
everyone _ O
. _ O

I _ O
would _ O
like _ O
to _ O
take _ O
this _ O
opportunity _ O
to _ O
place _ O
on _ O
record _ O
my _ O
immense _ O
gratitude _ O
to _ O
our _ O
employees _ O
, _ O
who _ O
rise _ O
to _ O
the _ O
occasion _ O
every _ O
time _ O
, _ O
and _ O
help _ O
us _ O
deliver _ O
consistently _ O
. _ O

I _ O
also _ O
thank _ O
every _ O
stakeholder _ O
who _ O
has _ O
vested _ O
their _ O
confidence _ O
in _ O
us _ O
. _ O

I _ O
solicit _ O
your _ O
continued _ O
cooperation _ O
and _ O
trust _ O
as _ O
we _ O
chart _ O
our _ O
way _ O
forward _ O
. _ O

Best _ O
regards _ O
, _ O
SAMIR _ O
MEHTA _ O
Executive _ O
Chairman _ O
13Consistency _ O
with _ O
Prudence _ O
CORPORATE _ O
OVERVIEW _ O

